Altamira Therapeutics Ltd. released its condensed consolidated interim financial results for the six months ended June 30, 2025. The company reported other operating income of $80,951, a significant increase from $34,298 in the same period in 2024. However, the operating loss for the period was $2.63 million, an improvement compared to a loss of $3.92 million in the prior year. The research and development expenses decreased to $1.47 million from $1.96 million, while general and administrative expenses fell to $1.24 million from $1.99 million. Finance income notably rose to $1.66 million from $513. The company is exploring avenues for generating $2.8 to $3.5 million in funding within 12 months from the reporting date, primarily through the spin-off of its RNA delivery business and revenue from licensing, partnering activities, and potential grant funding. Cash and cash equivalents at the end of the period were recorded at a deficit of $10,839, compared to a surplus of $65,455 at the end of the corresponding period in 2024.